An observational study in Respiratory Insufficiency and Chronic Respiratory Failure, sponsored by Istanbul Saglik Bilimleri University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Istanbul Saglik Bilimleri University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Respiratory Insufficiency with a site in Turkey — 10 open to participants now, 10 under way, none of them phase 3. Respiratory Insufficiency · Turkey.
Among the 51 studies in Respiratory Insufficiency with a site in Turkey, this one is the 11th largest by planned enrollment of the 25 observational ones that give a count, is one of 5 that started in 2026, is one of 25 observational ones, and was the 47th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →10 of the 51 studies in Respiratory Insufficiency with a site in Turkey are open now. Recruiting first, the newest first:
Kocaeli City Hospital · Sites in Turkey
Ages 18+
Medipol University · Sites in Turkey, Chile, Egypt and 3 more countries
Ages 18–89
Lokman Hekim Üniversitesi · Sites in Turkey
Ages 5–15 · Healthy volunteers
Başakşehir Çam & Sakura City Hospital · Sites in Turkey
Ages 18+
Nilgün Erdoğan · Sites in Turkey
Ages 18+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 100 across 456 observational studies indexed under Respiratory Insufficiency.
Median enrollment 90 across the 26 interventional studies, 108 across the 25 observational. Of the 38 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 51 have an industry lead sponsor. The 10 most frequent:
Istanbul Saglik Bilimleri University is the lead sponsor of 60 studies on the registry; 15 are open to participants now.
Istanbul Saglik Bilimleri University has 1 study filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Respiratory Insufficiency with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07098611Medipol UniversityA New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score | 2026-12-30 |
| NCT07805603Medipol UniversityHERMES: Quality and Safety of Advanced Respiratory Support During Patient Transport | 2027-06-01 |
| NCT07610122Istanbul Saglik Bilimleri UniversityValidation of the Turkish Version of the S3-NIV Questionnaire | 2027-06-30 |
| NCT07909226Kocaeli City HospitalLactate/Albumin Ratio and Mortality in Respiratory Failure | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies in Respiratory Insufficiency with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the psychometric properties, including reliability and validity, of the Turkish version of the Severe Respiratory Insufficiency Questionnaire for Non-Invasive Ventilation (S3-NIV). The S3-NIV is a specific tool designed to assess difficulties and compliance in patients receiving home non-invasive ventilation. A total of 120 stable patients using home NIV for at least 3 months will be enrolled across multiple centers.
Following the official linguistic validation process authorized by the Mapi Research Trust, this multi-center observational study will assess the psychometric validity of the Turkish S3-NIV questionnaire. Patients will complete the 11-item S3-NIV questionnaire alongside a sociodemographic and clinical data form. To evaluate test-retest reliability, a randomly selected subgroup of patients (n=40) will re-complete the questionnaire 14 to 15 days after the initial administration. Internal consistency, construct validity (via factor analysis), and criterion validity (correlations with clinical parameters such as daily NIV usage hours and blood gas values) will be analyzed.
Adult patients with chronic respiratory failure who are followed up in the outpatient clinic and have been using a home non-invasive ventilation (NIV) device for at least 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with chronic respiratory failure who have been using home non-invasive ventilation (NIV) for at least 3 months and are in a clinically stable phase.
Other: Turkish Version of the S3-NIV Questionnaire
An 11-item self-administered questionnaire designed to evaluate the difficulties and compliance of patients using home non-invasive ventilation (NIV).
Internal Consistency and Construct Validity of the Turkish S3-NIV
Evaluated using Cronbach's alpha coefficient for internal consistency and Confirmatory/Exploratory Factor Analysis (CFA/EFA) to confirm the structural validity of the 11-item scale.
Time frame: Baseline (Day 0)
Test-Retest Reliability
Evaluated using the Intraclass Correlation Coefficient (ICC) between the first and second administrations of the questionnaire in a randomly selected subgroup.
Time frame: 14 to 15 days after baseline
Plan to share: No — A decision on sharing individual participant data (IPD) has not yet been made. Data sharing may be considered upon reasonable request to the principal investigator after the publication of the study results.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.
Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 13 months is below that.
Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Oct 2026 → Jun 2027 and completion Dec 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Saglik Bilimleri University